Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-575-8 | CAS number: 577953-88-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: predictions from Basic Data set
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: A qualitative assessment of the toxicokinetics of the substance has been performed, based upon its physical properties and the results of toxicological studies.
Data source
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7c: Endpoint specific guidance Version 2.0 November 2014
- GLP compliance:
- no
Test material
- Reference substance name:
- N-cyclohexylcyclohexanamine 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetate
- EC Number:
- 611-575-8
- Cas Number:
- 577953-88-9
- Molecular formula:
- C47H59ClN2O3S
- IUPAC Name:
- N-cyclohexylcyclohexanamine 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetate
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- White powder with lumps
Stored at room temperature
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- other:
Results and discussion
Bioaccessibility (or Bioavailability)
- Bioaccessibility (or Bioavailability) testing results:
- key physical properties:
Molecular weight: 767.5 comprising of Montelukast (586.2 Da) and Dicyclohexylamine (181.3 Da)
Water solubility: The flask method was applied for the determination of the water solubility of Montelukast Dicyclohexylamine Salt. The water solubility of the test substance at 20°C based on Dicyclohexylamine was 0.0464 g/l. The water solubility of the test substance at 20°C based on Montelukast was ≤ 0.5 mg/l. The pH of the aqueous samples was 6.4 – 8.3.
Partition co-efficient (log Pow): One key study was completed for partition coefficient according to EC A.8 and OECD method 107 following GLP. As the substance is a salt a log Pow value was determined for the cationic and anioic portion of the substance. Based on Dicyclohexylamine the log Pow Value is 0.2 and based on Montelukast the log Pow is 4.9 at 20°C by the shake flask method.
Particle size: From the particle size distribution 2.02 % of particles have a diameter of less than or equal to 10µm (respirable fraction);
6.3% of particles have a diameter of less than or equal to 30µm (Thoracic fraction); 25%
of particles have a diameter of less than or equal to 100µm (Inhalable fraction).
Dissociation constant: not determined
Hydrolysis: not determined
Structural alerts- The substance comprises of a salt of dicyclohexylamine and montelukast acid. The substance can be expected to dissociate in physiological fluids to its component ions. Systemic effects have been predicted on the results of studies conducted on the consituent ions.
Any other information on results incl. tables
acute oral toxicity: discriminating dose 2000mg/kg bw
acute dermal toxicity: discriminating dose 2000 mg/kg bw
repeat dose oral toxicity: The registered substance comprises of two component ions which can be expected to dissociate into their respective species following oral administration and exposure to gastric fluids;
systemic effects were observed in repeat dose toxicity studies conducted on the constituent ions, DCHA and Montelukast
Reproductive toxicity: The chemical species have been examined in separate reproductive screening studies which resulted in NOAEL of 40 mg/kg bw/day and 100 mg/kg bw/day for DCHA and Montelukast respectively.
skin exposure- non irritant and non-sensitising
eye exposure- non-irritant
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): low bioaccumulation potential based on study results
Oral: evidence presented by the repeat dose and reproductive toxicity studies indicates that the substance is absorbed following administration in aqueous or non-aqueous vehicles; this is despite of the very low water solubilities of the constituent ions (46.4 mg/l DCHA; ≤ 0.5 mg/l Montelukast) and lipophilic partition co-efficient (DCHA 0.2; Montelukast 4.9). Fetal/embronic effects (decreased weight gain) also indicate that the substances are readily distributed once absorbed.
Inhalation: Particle size (<45µm) would indicate that the substance is respirable- the low water solubility will enhance the penetration to the lower
respiratory tract. Given that oral absorption of the substance has been demonstrated in the 28 repeat dose study, it can be expected that absorption by the inhalation route is also likely.
Dermal absorption: based upon the physical properties of molecular weight, water solubility and partition coefficient- dermal uptake is expected to be low.
Metabolism: Studies in rats indicate that hepatic metabolism (EFCOD) is not induced by exposure to Montelukast; in vitro studies with liver slices/homogenates indicate that DCHA is not subject to hepatic metabolism.
Excretion: Following oral dosing in rabbits, Significant amounts of DCHA (27-44%) are excreted unmodified within 72 hours. 86% of montelukast is eliminated in faeces with <0.2% excreted in the urine. - Executive summary:
Based upon the results of repeat dose toxicity testing and the physical properties of the substance, it can be predicted that absorption and distribution can be expected by the oral route; a default value of 50% bioavailability is assigned for this route.
Uptake is unlikely by the dermal route, a default value of 10% is assigned based upon the physical properties of the substance.
Based on the particle size distribution, only 6% of the registered substance would reach the lungs, with 25% being available
through oral/inhalation routes, therefore a value of 25% bioavailability by the inhalation route is justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.